Development and validation of machine learning models for predicting STAS in stage I lung adenocarcinoma with part-solid and solid nodules: a two-center study.
Source check: Source checked. Not independent scientific confirmation.
Finding: Original Frontiers Methods/Results: ML models predict STAS in stage-I lung adenocarcinoma using 353-patient training data and independent 120-patient second-center validation; tuning used stratified 10-fold CV in training only. Retrospective multicenter validation; narrow diagnostic prediction. The bibliographic records retrieved do not state an author affiliation.
Technology: Original Frontiers Methods/Results: ML models predict STAS in stage-I lung adenocarcinoma using 353-patient training data and independent 120-patient second-center validation; tuning used stratified 10-fold CV in training only. Retrospective multicenter validation; narrow diagnostic prediction.
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- Original Frontiers Methods/Results: ML models predict STAS in stage-I lung adenocarcinoma using 353-patient training data and independent 120-patient second-center validation; tuning used stratified 10-fold CV in training only. Retrospective multicenter validation; narrow diagnostic prediction.
- Test and result
- Original Frontiers Methods/Results: ML models predict STAS in stage-I lung adenocarcinoma using 353-patient training data and independent 120-patient second-center validation; tuning used stratified 10-fold CV in training only. Retrospective multicenter validation; narrow diagnostic prediction.
- Limitation / still unknown
- Original Frontiers Methods/Results: ML models predict STAS in stage-I lung adenocarcinoma using 353-patient training data and independent 120-patient second-center validation; tuning used stratified 10-fold CV in training only. Retrospective multicenter validation; narrow diagnostic prediction. Methods/Results specify cohort, reference/outcome, split or experimental comparator and limitations.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1682633/full
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.